These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 7517256)

  • 1. Controlled trial of orally administered immunoglobulin following bone marrow transplantation.
    Copelan EA; Bechtel TP; Klein JP; Klein JL; Tutschka P; Kapoor N; Featheringham NC; Avalos BR
    Bone Marrow Transplant; 1994 Jan; 13(1):87-91. PubMed ID: 7517256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation.
    Winston DJ; Antin JH; Wolff SN; Bierer BE; Small T; Miller KB; Linker C; Kaizer H; Lazarus HM; Petersen FB; Cowan MJ; Ho WG; Wingard JR; Schiller GJ; Territo MC; Jiao J; Petrarca MA; Tonetta SA
    Bone Marrow Transplant; 2001 Jul; 28(2):187-96. PubMed ID: 11509937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized placebo-controlled trial of lisofylline in HLA-identical, sibling-donor, allogeneic bone marrow transplant recipients. The Lisofylline Marrow Transplant Study Group.
    List AF; Maziarz R; Stiff P; Jansen J; Liesveld J; Andrews F; Schuster M; Wolff S; Litzow M; Karanes C; Dahlberg S; Kirkhart B; Bianco JA; Singer JW
    Bone Marrow Transplant; 2000 Feb; 25(3):283-91. PubMed ID: 10673700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of low-dose oral glutamine on painful stomatitis during bone marrow transplantation.
    Anderson PM; Ramsay NK; Shu XO; Rydholm N; Rogosheske J; Nicklow R; Weisdorf DJ; Skubitz KM
    Bone Marrow Transplant; 1998 Aug; 22(4):339-44. PubMed ID: 9722068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease.
    Chao NJ; Parker PM; Niland JC; Wong RM; Dagis A; Long GD; Nademanee AP; Negrin RS; Snyder DS; Hu WW; Gould KA; Tierney DK; Zwingenberger K; Forman SJ; Blume KG
    Biol Blood Marrow Transplant; 1996 May; 2(2):86-92. PubMed ID: 9118303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Allogenic transplantation of bone marrow in hematologic diseases. Preparation and completion of transplantation at the Hematology Clinic in Novi Sad].
    Pejin D; Popović S; Dokić M; Felle D; Stefanović N
    Acta Chir Iugosl; 1990; 37 Suppl 1():11-5. PubMed ID: 2109441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation.
    Nemunaitis J; Rosenfeld CS; Ash R; Freedman MH; Deeg HJ; Appelbaum F; Singer JW; Flomenberg N; Dalton W; Elfenbein GJ
    Bone Marrow Transplant; 1995 Jun; 15(6):949-54. PubMed ID: 7581096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gut mucosa barrier preservation by orally administered IgA-IgG to patients undergoing bone marrow transplantation: a randomised pilot study.
    Johansson JE; Ekman T
    Bone Marrow Transplant; 1999 Jul; 24(1):35-9. PubMed ID: 10435732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral eicosapentaenoic acid for complications of bone marrow transplantation.
    Takatsuka H; Takemoto Y; Iwata N; Suehiro A; Hamano T; Okamoto T; Kanamaru A; Kakishita E
    Bone Marrow Transplant; 2001 Oct; 28(8):769-74. PubMed ID: 11781629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical correlations with cyclosporine blood levels after allogeneic bone marrow transplantation: an analysis of four different assays.
    Atkinson K; Downs K; Ashby M; Biggs J
    Transplant Proc; 1990 Jun; 22(3):1331-4. PubMed ID: 2190395
    [No Abstract]   [Full Text] [Related]  

  • 12. Does oxypentifylline reduce the intensity of acute graft-versus-host disease following allogeneic bone marrow transplantation?
    Ghosh K; Hutchinson RM
    Haematologia (Budap); 1996; 28(1):45-51. PubMed ID: 9283904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone marrow transplantation: past experiences and future prospects.
    Thomas ED
    Semin Oncol; 1992 Jun; 19(3 Suppl 7):3-6. PubMed ID: 1615331
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of GVHD on the recovery of NK cell activity and LAK precursors following BMT.
    Keever CA; Klein J; Leong N; Copelan EA; Avalos BR; Kapoor N; Cunningham I; Tutschka PJ
    Bone Marrow Transplant; 1993 Sep; 12(3):289-95. PubMed ID: 8241989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial.
    Schmitz N; Beksac M; Bacigalupo A; Ruutu T; Nagler A; Gluckman E; Russell N; Apperley J; Szerm J; Bradstock K; Buzyn A; Schlegelberger B; Matcham J; Gratwohl A
    Haematologica; 2005 May; 90(5):643-8. PubMed ID: 15921379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical cyclosporin A for treatment of oral chronic graft-versus-host disease.
    Epstein JB; Reece DE
    Bone Marrow Transplant; 1994 Jan; 13(1):81-6. PubMed ID: 8019458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute graft-versus-host disease following bone marrow transplantation in humans: prognostic factors. Advisory Committee of the International Bone Marrow Transplant Registry.
    Bortin MM
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2655-7. PubMed ID: 3274576
    [No Abstract]   [Full Text] [Related]  

  • 18. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
    Aschan J; Ringdén O
    Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mixed hematopoietic chimerism for preventing graft-versus-host disease in mice receiving rat bone marrow transplantation.
    Pei FY; Li CF; Tang XF
    Di Yi Jun Yi Da Xue Xue Bao; 2003 Jul; 23(7):709-13. PubMed ID: 12865228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donors: single center experience.
    Lamparelli T; Van Lint MT; Gualandi F; Occhini D; Barbanti M; Sacchi N; Ficai G; Ghinatti C; Ferrara GB; Delfino L; Pozzi S; Morabito A; Zikos P; Vitale V; Corvo R; Frassoni F; Bacigalupo A
    Bone Marrow Transplant; 1997 Dec; 20(12):1057-62. PubMed ID: 9466278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.